No survival improvement from bevacizumab for patients with newly diagnosed glioblastoma
Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients with newly diagnosed glioblastoma, an often deadly brain cancer, researchers reported.